Status:
COMPLETED
Nadroparin Anticoagulation for Continuous Venovenous Hemofiltration
Lead Sponsor:
Onze Lieve Vrouwe Gasthuis
Conditions:
Kidney
Acute Renal Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The low molecular weight heparin nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. Continuous hemofiltration is a renal replacement modality for intensive care patie...
Detailed Description
The low molecular weight heparin (LMWH) nadroparin is used for anticoagulation of the extracorporeal hemofiltration circuit. LMWH accumulate in patients with chronic renal failure. Continuous venoveno...
Eligibility Criteria
Inclusion
- acute renal failure requiring renal replacement therapy
Exclusion
- (recent) bleeding or a suspicion of bleeding necessitating transfusion,
- need of therapeutic anticoagulation or
- (suspected) heparin-induced thrombocytopenia
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00965328
Start Date
February 1 2007
End Date
May 1 2008
Last Update
August 25 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Onze Lieve Vrouwe Gasthuis
Amsterdam, Netherlands, 1090AC